Galena’s Immunotherapy GALE-301 Shows Promise in Preventing Ovarian Cancer Recurrence

Galena’s Immunotherapy GALE-301 Shows Promise in Preventing Ovarian Cancer Recurrence
The cancer immunotherapy GALE-301 is a promising therapeutic approach to prevent cancer recurrence in women with ovarian and endometrial cancers who underwent surgery, according to data from the final analysis of a Phase 1/2a trial. Two years after undergoing surgery, 77% of women receiving the optimal dose of GALE-301 in the trial remained disease-free, compared with 44% of women who had not received the vaccine. The findings were recently presented by Dr. Larry Maxwell at the Annual Meeting on Women’s Cancer 2017 hosted by the Society of Gynecologic Oncology. The presentation was titled, “Analysis of a Phase I/IIa Trial Assessing E39+GM-CSF, a Folate Binding Protein Vaccine, to Prevent Recurrence in Ovarian and Endometrial Cancer Patients.” Galena Biopharma's GALE-301 is a combination of a peptide (E39) derived from the folate binding protein (FBP) and the immune adjuvant granulocyte macrophage-colony stimulating factor (GM-CSF). FBP is highly expressed in ovarian, endometrial, and breast cancers, and is a well-validated target for cancer therapies. Small portions of this protein, like the E39 peptide, have the ability to stimulate cytotoxic T-cells that recognize and destroy FBP-positive cells. The single-center, randomized Phase 1/2a trial (NCT01580696) was designed to assess the safety and effectiveness of GALE-301 in patients with primary or recurrent endometrial, ovarian, fallopian tube, or peritoneal cancer. The trial enrolled 51 patients, 40 of whom had just received standard of care surgery. The remaining 11 had been treated for recurrent disease. All patients we
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *